Michal Chalupka

Michal Chalupka

Auto-generated profile, based on publicly available information

Michal Chalupka

Department of Arrhythmias and Cardiac Pacing Paediatric Cardiac Centre, National Institute of Cardiovascular Diseases in Bratislava Bratislava Slovakia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
MBMarko Bjeloševič
Marko Bjeloševič
VIViera Illíková
Viera Illíková
JTJaroslav Tomko
Jaroslav Tomko
POPeter Olejník
Peter Olejník
MCMichal Chalupka
Michal Chalupka
RHRobert HATALA
Robert HATALA

8 March 2026 in Journal of Arrhythmia
Verified
Journal Article
Open access
MBMarko Bjeloševič
Marko Bjeloševič
POPeter Olejník
Peter Olejník
JTJaroslav Tomko
Jaroslav Tomko
MCMichal Chalupka
Michal Chalupka
VIViera Illíková
Viera Illíková
Aims: Implantable cardioverter‐defibrillator (ICD) therapy in children, particularly for primary prevention, remains under investigation, with limited data from less affluent European countries. With increasing use of fully subcutaneous (S‐ICD) and extravascular (EV‐ICD) systems, we analyzed epidemiology, indications, complications, and outcomes in pediatric ICD recipients at our tertiary center. Methods: This retrospective, population‐based, nationwide, single‐center study consecutively analyzed medical records from 2012 to 2025. Patients aged 0–18 years who underwent ICD implantation were included. Kaplan–Meier analyses were performed for shock‐free and mortality endpoints. Results: Forty‐nine patients were included, corresponding to an estimated national incidence of approximately one ICD implantation per 22 000 live births. ICDs were predominantly implanted for secondary prevention (80%). Long QT syndrome (32%) and hypertrophic cardiomyopathy (22%) were the most frequent diagnoses. During 207 patient‐years of follow‐up (median follow‐up 4 years), appropriate ICD shocks occurred in 27% of patients exclusively in the secondary prevention group. No appropriate therapies occurred in the primary prevention group despite higher overall mortality. Inappropriate shocks occurred in 22% of patients. Device‐related major complications affected 17% of implanted systems. Median transvenous ICD battery longevity was 6.5 years. Overall mortality was 6%, all related to underlying structural heart disease, with no ICD‐related deaths. S‐ICDs demonstrated a favorable acute and mid‐term safety profile in patients without pacing requirements. Conclusions: Pediatric ICD therapy is limited by substantial device‐related morbidity and imperfect risk stratification for primary prevention. The emerging S‐ICD and EV‐ICD systems represent promising, less invasive alternatives for selected pediatric patients.

30 October 2025 in EP Europace
Verified
Journal Article
Open access
Massimo Stefano SilvettiMassimo Stefano Silvetti
Massimo Stefano Silvetti
LBLuc Bruyndonckx
Luc Bruyndonckx
VWVictor Waldmann
Victor Waldmann
RGRoman Gebauer
Roman Gebauer
LKLászló Környei
László Környei
FDFabrizio Drago
Fabrizio Drago
Aims: Subcutaneous implantable cardioverter-defibrillators (S-ICDs) are effective in patients who require protection from sudden cardiac death while avoiding the long-term risks associated with transvenous leads. However, data on their real-world performance in paediatric and young patients remain limited. This study aims to evaluate the safety and efficacy of S-ICDs in a large, multicentre cohort of paediatric and young patients across Europe, with a focus on contemporary implantation practices and clinical outcomes. Methods and results: This is an international, multicentre, observational, retrospective registry on S-ICD outcome in paediatric and young adult patients with congenital heart defects (CHD), cardiomyopathies, channelopathies, and idiopathic ventricular fibrillation (IVF). Data were collected on implantation techniques, acute and long-term outcomes, including defibrillation efficacy, inappropriate (IAS) and appropriate shocks, and complications. Follow-up data were analysed to assess device performance and safety. A total of 223 patients (mean age: 15 ± 3 years; 59% male, 53% cardiomyopathies, 18% channelopathies, 15% IVF, 14% CHD) were included. Most patients underwent implantation using an intermuscular (65%) and two-incision technique (88%). Acute defibrillation success was 100%, and no intraoperative complications occurred. The median follow-up was 28 (IQR: 12–55) months. Appropriate shocks were delivered in 41 (18%) patients (26% rate at 5 years). The first shock was effective in 92% of discrete episodes. The IAS and the complication rates were 20% and 5% at 5 years. Older age, intermuscular pocket, and two-incision technique were associated with fewer complications. Conclusion: This multicentre S-ICD European registry in paediatric and young patients demonstrated favourable outcomes, low IAS, and complication rates.